Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19

NCT05057897 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05057897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05057897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Terminated
Start date
January 31, 2022
Completion date
April 19, 2023
Enrollment
34 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2